{"id":"W2764109025","doi":"10.1111/bjd.16050","title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","year":2017,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Etanercept; Medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Internal medicine; Post-hoc analysis; Dosing; Dermatology; Secukinumab; Tumor necrosis factor alpha; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004399853,0.000488303,0.003460529,0.0006690194,0.0007117775,0.0001035735,0.0007521728,0.0005423175,0.0001385248],"category_scores_gemma":[0.0007114651,0.0004119866,0.001786631,0.0003158352,0.0005044253,0.0003455266,0.0001041415,0.0002657416,0.00002324939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002383661,"about_ca_system_score_gemma":0.0004734214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005861521,"about_ca_topic_score_gemma":0.003363907,"domain_scores_codex":[0.9967712,0.0003711208,0.001654297,0.0004483615,0.0001383361,0.0006167433],"domain_scores_gemma":[0.9944032,0.001122417,0.00266001,0.0006410721,0.001091632,0.00008170297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1104889,0.005322663,0.04939251,0.0001528561,0.3113245,0.003177389,0.001409837,0.0004307678,0.005269217,0.001237585,0.009991752,0.501802],"study_design_scores_gemma":[0.6363007,0.005889263,0.107567,0.0009760024,0.098912,0.02219784,0.002725862,0.00008279525,0.08968754,0.002051139,0.03172667,0.001883229],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.955327,0.03884382,0.0007034393,0.0005729662,0.002833103,0.0009080674,0.0004689026,0.00003046913,0.000312238],"genre_scores_gemma":[0.9936848,0.005019035,0.0003109695,0.00005227818,0.0001142459,0.00009617327,0.0001496609,0.00003531913,0.0005374617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5258117,"threshold_uncertainty_score":0.9998332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0660134355339033,"score_gpt":0.3257095382569747,"score_spread":0.2596961027230714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}